Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Oncolytics Biotech Inc (TSX: ONC )

2.340 -0.120 (-4.88%)
Streaming Delayed Price Updated: 3:59 PM EST, Jan 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 62,464
Open 2.430
Bid (Size) 2.340 (23)
Ask (Size) 2.400 (7)
Prev. Close 2.460
Today's Range 2.330 - 2.450
52wk Range 1.060 - 3.100
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Biotechs Race for New Treatments as Breast Cancer Therapeutics Market Could Reach $15 Billion by 2028
EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:GILD),(NYSE:BMY),(NASDAQ:RXDS),(NASDAQ:RNAZ) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence COVID-19
Oncolytics Biotech’s® Chinese Development Partner Adlai Nortye Presents Interim Clinical Data Further Demonstrating the Anti-Cancer Activity of Pelareorep-Paclitaxel Combination Therapy in HR+/HER2- Metastatic Breast Cancer at the San Antonio Breast
Thirteen of fourteen (93%) evaluable patients achieved disease control, with twelve (86%) showing tumor shrinkage San Diego, CA and Calgary, AB – December 8, 2022 – Oncolytics Biotech® Inc.’s (NASDAQ:... 
Via FinancialNewsMedia

Performance

YTD
+5.88%
+5.88%
1 Month
+9.86%
+9.86%
3 Month
+38.46%
+38.46%
6 Month
+59.18%
+59.18%
1 Year
-0.43%
-0.43%

More News

Read More
Wave of FDA Fast Track Designations Sparks Renewed Interest in Biotech Sector That’s Heating Up
Via FinancialNewsMedia
Exposures Product Safety
Optimism Building for Advancing Pancreatic Cancer Treatment Therapies
Via FinancialNewsMedia
Exposures Product Safety
Oncolytics Biotech® Receives FDA Fast Track Designation for the Treatment of Advanced/Metastatic Pancreatic Cancer
Via FinancialNewsMedia
Exposures Product Safety
Big Developments Set to be Unveiled at This Year’s San Antonio Breast Cancer Symposium (SABCS)
Via FinancialNewsMedia
Biotech Sector Witnessing Growing Revenue Potential in Ongoing Battle Against Pancreatic Cancer
Via FinancialNewsMedia
Topics Death
Exposures Death
Biotech Sector Gaining Wins Against Pancreatic Cancer with Early Detection and New Therapies
Via FinancialNewsMedia
Biotechs with Evolving Therapies Have Potential to Revolutionize Treatments for Pancreatic Cancer
Via FinancialNewsMedia
Oncolytics Biotech® Presents Updated Clinical Data at SITC Annual Meeting Showing a 69% Objective Response Rate and Confirmed Complete Response in GOBLET Study’s Pancreatic Cancer Cohort
Via FinancialNewsMedia
Rising Incidence of Pancreatic Cancer Driving Demand for Advanced Treatment Therapies
Via FinancialNewsMedia
Exposures COVID-19
R&D Efforts to Improve Optimal Treatments for Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Progressing
Via FinancialNewsMedia
Topics Death
Exposures Death
Oncolytics Biotech® Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 37th Annual Meeting
Via FinancialNewsMedia
Global Pancreatic Cancer Therapeutics & Diagnostics Market Expected To Reach $5.6 Billion By 2027
Via FinancialNewsMedia
Oncolytics Biotech® and SOLTI Present New Clinical Biomarker Data Demonstrating Pelareorep’s Potential to Improve the Prognosis of Breast Cancer Patients at the ESMO Breast Cancer Meeting
Via FinancialNewsMedia
HER2-Targeted Therapies Introduced Early in Breast Cancer Treatment Offering Hope for Patients
Via FinancialNewsMedia
Exposures COVID-19
Promising Results Continue to Develop Optimism in Fight Against Cancers
Via FinancialNewsMedia
Advancements of CAR-T Cell Therapies Importance Grows While Cancer Cases Increasing
Via FinancialNewsMedia
Oncolytics Biotech® Partner Adlai Nortye Advances to the Second Dose Escalation Cohort of the Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment in Breast Cancer
Via FinancialNewsMedia
Optimism Builds for Promising Developments & New Drug Therapies Targeting Treatments for Breast Cancer
Via FinancialNewsMedia
Billions Flowing into Cancer Immunotherapy as Market Responds to Impressive Market Potential
Via FinancialNewsMedia
Groundbreaking Clinical Trials Accelerating New Treatment Options for Pancreatic Cancer
Via FinancialNewsMedia
Promising Research in Fight Against Breast Cancer Being Amplified by an Active Biotech Sector
Via FinancialNewsMedia
R&D Spending Increases Exponentially for Higher Standard of Breast Cancer Drug Treatments
Via FinancialNewsMedia
Topics Death Intellectual Property
Exposures Death Intellectual Property
Gastrointestinal Cancer Treatment Trials Driven by Rising Incidences of Colorectal Cancer
Via FinancialNewsMedia
Topics Death
Exposures Death
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.